• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Traumatic Brain Injury - Pipeline Review, H2 2012 Product Image

Traumatic Brain Injury - Pipeline Review, H2 2012

  • Published: October 2012
  • 151 pages
  • Global Markets Direct

Traumatic Brain Injury – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Traumatic Brain Injury - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Traumatic Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury. Traumatic Brain Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Traumatic Brain Injury.
- A review of the Traumatic Brain Injury products under development by companies READ MORE >

2
List of Tables 9
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Traumatic Brain Injury Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Traumatic Brain Injury 13
Traumatic Brain Injury Therapeutics under Development by Companies 15
Traumatic Brain Injury Therapeutics under Investigation by Universities/Institutes 19
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Traumatic Brain Injury Therapeutics – Products under Development by Companies 25
Traumatic Brain Injury Therapeutics – Products under Investigation by Universities/Institutes 27
Companies Involved in Traumatic Brain Injury Therapeutics Development 28
Sanofi-Aventis 28
Athersys, Inc. 29
Sangamo BioSciences, Inc. 30
Acorda Therapeutics, Inc. 31
Oxygen Biotherapeutics, Inc. 32
Lpath, Inc. 33
Neuren Pharmaceuticals Limited 34
RegeneRx Biopharmaceuticals, Inc. 35
Transition Therapeutics Inc. 36
Allon Therapeutics Inc. 37
Stem Cell Therapeutics Corp. 38
NeuroVive Pharmaceutical AB 39
M et P Pharma AG 40
D-Pharm Ltd. 41
KeyNeurotek Pharmaceuticals AG 42
Remedy Pharmaceuticals, Inc. 43
Adamas Pharmaceuticals, Inc. 44
NeuroNascent, Inc. 45
vasopharm GmbH 46
KYORIN Pharmaceutical Co., Ltd. 47
M's Science Corporation 48
Encore Therapeutics Inc. 49
Sinapis Pharma, Inc 50
BHR Pharma, LLC. 51
Cognosci, Inc. 52
STATegics, Inc. 53
Traumatic Brain Injury – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 60
MultiStem - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Lpathomab - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
progesterone - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DP-b99 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RGN-352 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Oxycyte - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
NNI-370 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ZFP TFs For Nerve Regeneration - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
VAS-203 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
KN38-7271 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
SA-4503 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MC-116 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MC-113 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NNZ-2566 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
conivaptan hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
minocycline - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
somatropin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
atorvastatin calcium - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
estrone sodium sulfate - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
cyclosporine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
methamphetamine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
epoetin alfa - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
pregnenolone - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
TT-301 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
nimodipine - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
progesterone - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
propranolol hydrochloride - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
AL-209 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
risperidone - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
darbepoetin alfa - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
citicoline sodium - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
citicoline sodium - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
progesterone - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
AC-105 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
MANF - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
methylphenidate hydrochloride - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
escitalopram oxalate - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
NVP-015 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
NVP-016 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
NR-2A Modulators - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
STS-E15 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
SAR-127963 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Hypertonic Saline - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Traumatic Brain Injury Therapeutics – Drug Profile Updates 124
Traumatic Brain Injury Therapeutics – Discontinued Products 141
Traumatic Brain Injury Therapeutics - Dormant Products 142
Traumatic Brain Injury – Product Development Milestones 143
Featured News & Press Releases 143
Sep 17, 2012: vasopharm's Traumatic Brain Injury Drug Exceeds Expectations In Phase IIa Exploratory Clinical Trial 143
Jul 24, 2012: BHR Pharma Reaches Enrollment Midpoint In SyNAPSe Phase III Trial 144
Jun 12, 2012: BHR Pharma Expands SyNAPSe Trial Into Thailand, China And Russia 144
Jun 07, 2012: Amarantus And Banyan Biomarkers Announce Positive Data From Traumatic Brain Injury Collaboration 145
May 25, 2012: RegeneRx Announces Publication Of Tß4 Data In Journal Of Neurosurgery 145
May 03, 2012: Oxygen Biotherapeutics Secures Long-Term Clinical Supply Of Oxycyte 146
Apr 25, 2012: Lpath Receives US Patent For Anti-LPA Antibody, Lpathomab 147
Apr 19, 2012: vasopharm Completes Patient Treatment In Phase IIa NOSTRA Trial With VAS203 147
Apr 02, 2012: Medistem Collaborates With Loma Linda University on Treatment of Traumatic Brain Injury Using Endometrial Regenerative Cells 148
Mar 21, 2012: BHR Pharma's SyNAPSe Trial Reaches Important Enrollment Milestone 148
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Tables
Number of Products Under Development for Traumatic Brain Injury, H2 2012 13
Products under Development for Traumatic Brain Injury – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Investigation by Universities/Institutes, H2 2012 27
Sanofi-Aventis, H2 2012 28
Athersys, Inc., H2 2012 29
Sangamo BioSciences, Inc., H2 2012 30
Acorda Therapeutics, Inc., H2 2012 31
Oxygen Biotherapeutics, Inc., H2 2012 32
Lpath, Inc., H2 2012 33
Neuren Pharmaceuticals Limited, H2 2012 34
RegeneRx Biopharmaceuticals, Inc., H2 2012 35
Transition Therapeutics Inc., H2 2012 36
Allon Therapeutics Inc., H2 2012 37
Stem Cell Therapeutics Corp., H2 2012 38
NeuroVive Pharmaceutical AB, H2 2012 39
M et P Pharma AG, H2 2012 40
D-Pharm Ltd., H2 2012 41
KeyNeurotek Pharmaceuticals AG, H2 2012 42
Remedy Pharmaceuticals, Inc., H2 2012 43
Adamas Pharmaceuticals, Inc., H2 2012 44
NeuroNascent, Inc., H2 2012 45
vasopharm GmbH, H2 2012 46
KYORIN Pharmaceutical Co., Ltd., H2 2012 47
M's Science Corporation, H2 2012 48
Encore Therapeutics Inc., H2 2012 49
Sinapis Pharma, Inc, H2 2012 50
BHR Pharma, LLC., H2 2012 51
Cognosci, Inc., H2 2012 52
STATegics, Inc., H2 2012 53
Assessment by Monotherapy Products, H2 2012 54
Assessment by Stage and Route of Administration, H2 2012 56
Assessment by Stage and Molecule Type, H2 2012 59
Traumatic Brain Injury Therapeutics – Drug Profile Updates 124
Traumatic Brain Injury Therapeutics – Discontinued Products 141
Traumatic Brain Injury Therapeutics – Dormant Products 142

List of Figures
Number of Products under Development for Traumatic Brain Injury, H2 2012 13
Products under Development for Traumatic Brain Injury – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 54
Assessment by Route of Administration, H2 2012 55
Assessment by Stage and Route of Administration, H2 2012 56
Assessment by Molecule Type, H2 2012 57
Assessment by Stage and Molecule Type, H2 2012 58

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos